Clinical trials: sponsored by Ruijin Hospital
Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
This is a prospective, multicenter, randomized controlled trial designed to evaluate the efficacy and safety of venetoclax-enhanced BUCY (Ven-BUCY) conditioning compared to the standard BUCY regimen in patients with high-risk…
- Conditions
- Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes, High-Risk Myelodysplastic Syndromes
- Trial name
- Ven-BUCY (NCT07183878)
- Testing
- Venetoclax, Busulfan (BU)
- Where
- China
- Volunteers
- 138 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Colon Adenocarcinoma, Stage I Colon Cancer
Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma
This multicenter prospective observational cohort study will enroll 392 patients with stage I-III colon adenocarcinoma who undergo curative resection and whose tumors harbor at least one prespecified oncogenic driver mutation…
- Conditions
- Colon Adenocarcinoma, Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
- Trial name
- ADX-DRIVER-CRC (NCT07795528)
- Testing
- Longitudinal ctDNA-MRD NGS testing at scheduled postoperative time points
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Ruijin Hospital
Acute Lymphoblastic Leukemia, B-precursor
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
This is a prospective, multicenter, randomized controlled trial designed to evaluate whether short-term blinatumomab intensification before allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival…
- Trial name
- NCT07003737
- Testing
- Blinatumomab, Consolidation Chemotherapy or Direct Allogeneic HSCT
- Where
- China
- Volunteers
- 114 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Constipation - Functional
Breath Gases, Gut Flora, and Immunity in Children With Constipation
Constipation is a common problem in children that can affect their daily life, school performance, and social activities. Researchers have found that the bacteria living in our intestines (called "gut microbiome") may play an…
- Trial name
- NCT07797491
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Chronic Graft Versus Host Disease in Eye
Observational Cohort Study on Ocular Chronic Graft-Versus-Host Disease
This study is a multicenter, prospective, observational cohort study designed to enroll a total of 340 patients undergoing allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT07794800
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Ruijin Hospital
Hematopoietic Stem Cell Transplantation (HSCT), cGVHD
Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD
This prospective, randomized, open-label, multicenter trial aims to compare second-line treatment strategies for hepatic cGVHD after allo-HSCT.
- Conditions
- Hematopoietic Stem Cell Transplantation (HSCT), cGVHD, Hepatic cGVHD, Belumosudil
- Trial name
- NCT07794514
- Testing
- Ruxolitinib treatment, Belumosudil treatment, Belumosudil Switch to Ruxolitinib
- Where
- China
- Volunteers
- 170 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT)
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy
The goal of this clinical trial is to evaluate the efficacy and safety of Iptacopan as a second-line treatment for high-risk hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA).
- Trial name
- NCT07347990
- Testing
- iptacopan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Parkinson's Disease (PD)
STN-tTIS With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's Disease
The goal of this clinical trial is to compare the efficacy and safety of different Intervention Intervals of subthalamic nucleus-targeted transcranial temporal interference stimulation (STN-tTIS) in patients with Parkinson…
- Trial name
- NCT07774312
- Testing
- STN-tTIS Once Weekly, STN-tTIS Twice Weekly, STN-tTIS Five Times Weekly
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Functional Gastrointestinal Disorders (FGIDs), Infant Discomfort
Effects of Goat Milk Formula on Gastrointestinal Comfort and Growth in Infants
Infant gastrointestinal discomfort is common in early life and can affect feeding, sleep, and overall well-being. Goat milk formula, due to its unique protein composition and smaller fat globules, may be easier to digest and…
- Trial name
- NCT07778927
- Testing
- Goat Milk Formula, Cow Milk Formula
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Parkinsonian Disorders, Machine Learning
Machine Vision Based MDS-UPDRS III Machine Rating
The Movement Disorders Society (MDS) Unified Parkinson's Disease Rating Scale (UPDRS) Part III (MDS-UPDRS III) is the primary assessment method for motor symptoms in Parkinson's disease patients.
- Trial name
- NCT05906719
- Testing
- video recording
- Where
- 8 sites in China
- Volunteers
- 1,679 people
- Sponsor
- Ruijin Hospital
Solid Tumor
Clinical Applications of FAPI PET in Solid Tumors
The study systematically evaluates the diagnostic performance of FAPI-RuiJ and FAPI-04 PET/CT or PET/MR in various solid tumor types, and is expected to provide a novel molecular imaging tool for early lesion detection, accurate…
- Trial name
- NCT07776899
- Testing
- FAPI-RuiJ, FAPI-04
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital
Lymphoma, B-Cell Refractory
Exploration of Circular RNA in B-cell Hematologic Malignancies
This is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric…
- Trial name
- NCT07774572
- Testing
- Investigational product (IP)
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Essential Tremor
Non-Invasive Neuromodulation for Essential Tremor: Long-Term Safety and Effectiveness Study
This is a prospective, single-center, single-arm, open-label clinical study designed to evaluate the long-term efficacy and safety of non-invasive neuromodulation using transcutaneous afferent patterned stimulation (TAPS) in…
- Trial name
- NCT07774598
- Testing
- Transcutaneous Afferent Patterned Stimulation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
DLBCL
Pirtobrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL
This trial is a prospective, multi-center, single-arm clinical research. The intention is to evaluate the efficacy and safety of pirtobrutinib combined with BEAM as a pretreatment regimen for ASCT in relapsed and refractory DLBCL…
- Trial name
- NCT07774299
- Testing
- pirtobrutinib combined with BEAM
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
Multiple System Atrophy
A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by autonomic dysfunction, parkinsonism, and cerebellar ataxia.
- Trial name
- NCT07774585
- Testing
- α-Syn H21 Monoclonal Antibody
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Ruijin Hospital
Gastric Cancer
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
This is a Single-arm, Open-label, Phase 1b/2 Study of IBI343 Combined with Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or…
- Trial name
- NCT07025889
- Testing
- IBI343, Sintilimab, Oxaliplatin
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Ruijin Hospital
Health, Children, Only
Characteristics of Intestinal Bacteria and Their Effects on Growth and Immune Function in Children at High Altitude
Microbes and the human body maintain a complex relationship of interaction and influence. Different regions, altitudes, and dietary habits have different degrees of influence on the composition of children's intestinal flora.
- Conditions
- Health, Children, Only, Gut Microbiota
- Trial name
- NCT06157346
- Where
- China
- Volunteers
- 298 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Cow's Milk Protein Allergy
Dietary Restriction Efficiency Assessment in CMPA
This clinical trial aims to evaluate and compare the efficacy of amino acid formula (AAF) and extensively hydrolyzed formula (eHF) in relieving symptoms in infants suspected of cow's milk protein allergy (CMPA) during the…
- Trial name
- NCT07199023
- Testing
- Amino Acid Formula (AAF), Extensively Hydrolyzed Formula (eHF)
- Volunteers
- 360 people
- Sponsor
- Ruijin Hospital
Cervical Cancer
Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients
To evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery.
- Trial name
- NCT05277688
- Testing
- adjuvant concurrent chemoradiotherapy, radiotherapy
- Where
- 2 sites in China
- Volunteers
- 340 people
- Sponsor
- Ruijin Hospital
Mild Allergic Symptoms in Infants, Infant Feeding Intolerance
Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy
This study is a prospective, multicenter, randomized controlled trial designed to evaluate the clinical efficacy, tolerance, and safety of a partially hydrolyzed whey protein formula in infants with mild allergic symptoms.
- Trial name
- NCT07449507
- Testing
- Partially Hydrolyzed Whey Protein Formula, Intact Cow's Milk Protein Formula
- Volunteers
- 160 people
- Sponsor
- Ruijin Hospital